Skip to main content

Find Clinical Trials

Home
Conditions
BRAF Mutant Melanoma

Clinical trial condition

BRAF Mutant Melanoma

Explore clinical trials studying BRAF Mutant Melanoma. Study availability and eligibility vary by location and protocol.

1 public trial 0 recruiting studies

Refine in advanced search Browse all conditions

BRAF Mutant Melanoma trial results

Completed

LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations

NCT01726738

Conditions: BRAF Mutant Melanoma, Melanoma, Neoplasms, +13 more
Locations: Lineberger Comprehensive Cancer Center, University of North Carolina Chapel Hill, North Carolina, United States

View Trial Details